PriceTargets.com logo

Nyxoah - NYXH Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $11.67
  • Forecasted Upside: 196.11%
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.94 As of 03/4/2026 05:00 PM ET
▲ +0.19 (5.07%)

This chart shows the closing price for NYXH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nyxoah Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NYXH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NYXH

Analyst Price Target is $11.67
▲ +196.11% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Nyxoah in the last 3 months. The average price target is $11.67, with a high forecast of $15.00 and a low forecast of $9.00. The average price target represents a 196.11% upside from the last price of $3.94.

This chart shows the closing price for NYXH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 investment analysts is to moderate buy stock in Nyxoah. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/3/2026
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/5/2026

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/29/2026Stifel NicolausLower TargetBuy ➝ Buy$12.00 ➝ $11.00
12/29/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/22/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/15/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/1/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/19/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/14/2025Piper SandlerReiterated RatingOverweight ➝ Overweight$12.00 ➝ $9.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
4/21/2025Stifel NicolausLower TargetBuy ➝ Buy$15.00 ➝ $14.00
4/8/2025HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/26/2025HC WainwrightLower TargetBuy ➝ Buy$17.00 ➝ $15.00
3/14/2025Stifel NicolausLower TargetBuy ➝ Buy$16.00 ➝ $15.00
12/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
11/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$16.00 ➝ $16.00
10/11/2024HC WainwrightLower TargetBuy ➝ Buy$18.00 ➝ $17.00
9/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
8/7/2024Cantor FitzgeraldLower TargetOverweight ➝ Overweight$17.00 ➝ $16.00
8/7/2024OppenheimerLower TargetOutperform ➝ Outperform$15.00 ➝ $13.00
8/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
6/24/2024Stifel NicolausLower TargetBuy ➝ Buy$27.00 ➝ $19.00
5/24/2024HC WainwrightLower TargetBuy ➝ Buy$22.00 ➝ $18.00
5/15/2024OppenheimerLower TargetOutperform ➝ Outperform$20.00 ➝ $15.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$22.00
5/15/2024Cantor FitzgeraldLower TargetOverweight ➝ Overweight$18.00 ➝ $17.00
5/15/2024Stifel NicolausReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
3/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $22.00
3/20/2024Stifel NicolausBoost TargetBuy ➝ Buy$20.00 ➝ $27.00
3/14/2024OppenheimerBoost TargetOutperform ➝ Outperform$17.00 ➝ $20.00
3/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00
3/6/2024Piper SandlerBoost TargetOverweight ➝ Overweight$15.00 ➝ $20.00
3/5/2024Stifel NicolausBoost TargetBuy ➝ Buy$10.00 ➝ $20.00
2/28/2024HC WainwrightBoost TargetBuy ➝ Buy$15.00 ➝ $18.00
2/9/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$10.00 ➝ $14.00
2/1/2024Piper SandlerBoost TargetOverweight ➝ Overweight$10.00 ➝ $15.00
12/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00
11/9/2023Piper SandlerLower TargetOverweight ➝ Overweight$11.00 ➝ $10.00
11/7/2023Stifel NicolausLower TargetBuy ➝ Buy$14.00 ➝ $10.00
9/26/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$11.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$11.00
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00
8/9/2023Piper SandlerLower TargetOverweight ➝ Overweight$12.00 ➝ $11.00
8/9/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$12.00 ➝ $11.00
7/31/2023HC WainwrightInitiated CoverageBuy$15.00
7/18/2023Robert W. BairdInitiated CoverageNeutral
5/18/2023Cantor FitzgeraldLower Target$17.00 ➝ $12.00
5/17/2023Stifel NicolausLower Target$16.00 ➝ $15.00
5/17/2023Piper SandlerLower Target$13.00 ➝ $12.00
3/23/2023Stifel NicolausLower TargetBuy$19.00 ➝ $16.00
11/9/2022Piper SandlerLower TargetOverweight$20.00 ➝ $13.00
8/9/2022Piper SandlerLower TargetOverweight$30.00 ➝ $20.00
4/20/2022OppenheimerInitiated CoverageOutperform$30.00
4/5/2022Wolfe ResearchInitiated CoverageMarket Perform$21.00
3/25/2022Piper SandlerLower Target$40.00 ➝ $30.00
12/21/2021Cantor FitzgeraldReiterated RatingOverweight
7/28/2021Cantor FitzgeraldInitiated CoverageOverweight$43.00
7/28/2021Piper SandlerInitiated CoverageOverweight$40.00
7/27/2021Stifel NicolausInitiated CoverageBuy$43.00
7/6/2021Kepler Capital MarketsReiterated RatingBuy
(Data available from 3/5/2021 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 2 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 2 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/4/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/3/2026
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/5/2026

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Nyxoah logo
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Read More

Today's Range

Now: $3.94
Low: $3.82
High: $4.00

50 Day Range

MA: $4.67
Low: $3.75
High: $5.23

52 Week Range

Now: $3.94
Low: $3.74
High: $11.87

Volume

42,958 shs

Average Volume

53,641 shs

Market Capitalization

$134.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Nyxoah?

The following equities research analysts have issued stock ratings on Nyxoah in the last year: HC Wainwright, Piper Sandler, Stifel Nicolaus, and Weiss Ratings.
View the latest analyst ratings for NYXH.

What is the current price target for Nyxoah?

0 Wall Street analysts have set twelve-month price targets for Nyxoah in the last year. Their average twelve-month price target is $11.67, suggesting a possible upside of 196.1%. HC Wainwright has the highest price target set, predicting NYXH will reach $15.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $9.00 for Nyxoah in the next year.
View the latest price targets for NYXH.

What is the current consensus analyst rating for Nyxoah?

Nyxoah currently has 1 sell rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NYXH.

What other companies compete with Nyxoah?

Other companies that are similar to Nyxoah include Beta Bionics, OrthoPediatrics, NeuroPace, Brainsway and Biosig Technologies. Learn More about companies similar to Nyxoah.

How do I contact Nyxoah's investor relations team?

The company's listed phone number is 321-022-2355 and its investor relations email address is [email protected]. The official website for Nyxoah is www.nyxoah.com. Learn More about contacing Nyxoah investor relations.